Skip to main content

I6T-MC-AMBG A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis

NCT03524092

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis

Associated Conditions

Colon

Principal Investigator

Sponsor

Lilly USA

The purpose of this study is to help answer the following research question: How an investigational drug, mirikizumab, compares with placebo in helping patients with ulcerative colitis over time.